Key result
DEGR-VIIa or TFPI increases minimal luminal diameter ~68% after arterial injury in rabbits.
Why the study?
The relation among the coagulation cascade, its individual proteins, and the response to vascular injury is largely undefined.
Does blockade of specific levels of the coagulation cascade reduce restenosis and neointimal hyperplasia in a rabbit atherosclerotic femoral artery injury model?
Does blockade of specific levels of the coagulation cascade reduce restenosis and neointimal hyperplasia in a rabbit atherosclerotic femoral artery injury model?
Blockade of early initiators of the extrinsic coagulation pathway (factor VII and tissue factor) significantly reduces angiographic restenosis and neointimal hyperplasia in a rabbit model of arterial injury.
Answers are grounded in this paper and cite their sources.
Supports coagulation blockade to limit restenosis in rabbit models; leaves open translation to human post-angioplasty outcomes.
BACKGROUND: The relation among the coagulation cascade, its individual proteins, and the response to vascular injury is largely undefined. We have evaluated the effect of four probes that block specific levels of coagulation cascade on neointimal hyperplasia in the atherosclerotic rabbit arterial injury model. METHODS AND RESULTS: Focal femoral atherosclerosis was induced by air-desiccation injury and hypercholesterolemic diet in 48 New Zealand White rabbits, followed by balloon angioplasty. Active-site inactivated factor VIIa (DEGR-VIIa), which blocks the binding of factor VIIa to tissue factor, was administered (n = 12 arteries) by intravenous bolus (1 mg/kg) at the time of balloon angioplasty and followed by infusion of 50 micrograms.kg-1.h-1 for 3 days; for the control (n = 13 arteries), 150 U heparin was injected as bolus and followed by infusion of saline at 50 microL.kg-1.min-1. Recombinant tissue factor pathway inhibitor (TFPI), which binds factor Xa and inhibits the tissue factor-factor VIIa complex and factor Xa, was given as a 1 mg/kg bolus followed by 15 micrograms.kg-1.min-1 infusion for 3 days (n = 17 arteries). Recombinant tick anticoagulant peptide (TAP; n = 15 arteries) and hirudin (n = 14 arteries), which block factor Xa and thrombin, respectively, were administered as a 1 mg/kg bolus followed by 5 micrograms.kg-1.min-1 infusion for 3 days. These three groups had their own controls (n = 14 arteries). There were no differences among treatment groups in preangioplasty and postangioplasty minimal luminal diameter (MLD) by angiography. The mean MLD 21 days after balloon angioplasty was significantly different between control and DEGR-VIIa-treated groups (0.74 +/- 0.25 and 1.24 +/- 0.27 mm, respectively; P = .0001) and between the TFPI-treated group and others (0.88 +/- 0.21 mm for control, 0.97 +/- 0.22 mm for hirudin-treated, 0.98 +/- 0.14 mm for TAP-treated, and 1.32 +/- 0.21 mm for TFPI-treated arteries; P = .0001 by ANOVA). By quantitative histological analysis, the ratio of neointimal cross-sectional area compared with the area of internal elastic lamina in the DEGR-VIIa-treated group was significantly less than control (0.48 +/- 0.12 versus 0.67 +/- 0.12, P = .0001), and the ratio of neointimal cross-sectional area to the area demarcated by the internal elastic lamina of the TFPI-treated group was significantly reduced compared with the other groups (0.46 +/- 0.20 for TFPI-treated, 0.67 +/- 0.15 for hirudin-treated, 0.61 +/- 0.15 for TAP-treated, and 0.64 +/- 0.13 for control groups; P = .003). CONCLUSIONS: Treatment with DEGR-VIIa or TFPI for 3 days in this rabbit atherosclerotic injury model reduced angiographic restenosis and decreased neointimal hyperplasia compared with controls. These findings highlight the importance of early initiators of the extrinsic coagulation pathway, especially factor VII and tissue factor, in the response to arterial injury.
No takes yet. Share an insight, caveat, or question.
Jang et al. (1995) studied Atherosclerotic arterial injury (restenosis model) (n=48). DEGR-VIIa or TFPI vs. Control (heparin bolus and saline infusion) was evaluated on Mean minimal luminal diameter (MLD) 21 days after balloon angioplasty (p=0.0001). Treatment with DEGR-VIIa or TFPI for 3 days in a rabbit atherosclerotic injury model increased minimal luminal diameter at 21 days compared with controls.
Synapse has enriched 10 related papers. Consider them for comparative context: